Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Symbravo ingredients mechanism of action?
Complera manufacturer?
Sun pharma bortezomib?
Drug patent watch trametinib?
Brenzavvy discontinuation?

Entresto sales?

See the DrugPatentWatch profile for Entresto

Entresto, a medication primarily prescribed for heart failure, has demonstrated significant sales growth. In the first quarter of 2024, Entresto achieved $1.77 billion in sales [1]. This marks a 14% increase compared to the same period in 2023, when sales were $1.55 billion [1]. Novartis, the manufacturer of Entresto, reported that the drug's strong performance contributed to its overall financial results [1].

How is Entresto performing year-over-year?


Entresto's sales have shown a consistent upward trend. For the full year 2023, the medication generated $6.49 billion in revenue [1]. This represents a substantial increase from the $5.97 billion in sales recorded in 2022 [1]. This sustained growth highlights the increasing adoption and effectiveness of Entresto in treating heart failure patients.

What is the projected future for Entresto sales?


Analysts and Novartis anticipate continued strong sales for Entresto. The drug's efficacy in reducing mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) underpins this positive outlook [2]. Novartis has previously indicated that Entresto has the potential to become one of its best-selling products, with expectations for peak sales to exceed $10 billion [3].

When does Entresto's patent expire?


The patent exclusivity for Entresto is a crucial factor in its long-term sales trajectory. DrugPatentWatch.com tracks patent information, and for Entresto (sacubitril/valsartan), various patents protect its composition of matter, methods of use, and manufacturing processes [4]. The exact expiration dates for these patents can vary, but generally, core patents for blockbuster drugs begin to expire within a 15 to 20-year window from their initial approval or filing [4]. This timeline is vital for understanding when generic competition might emerge.

What are the key drivers of Entresto's sales success?


Entresto's success is attributed to its demonstrated clinical benefits. Studies, such as the PARADIGM-HF trial, have shown that Entresto significantly reduces cardiovascular death and heart failure hospitalizations compared to enalapril, a standard ACE inhibitor [2]. This robust evidence base has led to widespread adoption by healthcare providers and inclusion in major treatment guidelines for heart failure. Furthermore, expansion into new patient populations, such as those with HFpEF, has also contributed to its market penetration.

What is the competitive landscape for heart failure treatments?


While Entresto has established a strong market position, the heart failure treatment landscape includes other medications and emerging therapies. These include ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, some of which also have cardiovascular benefits [2]. The development of novel therapies and potential generic entry after patent expiration could influence future market dynamics for Entresto.

What are the manufacturing and supply chain aspects of Entresto?


Novartis manages the manufacturing and supply chain for Entresto to ensure consistent availability for patients. Given its significant sales volume and global reach, efficient production and distribution are paramount. Any disruptions or changes in manufacturing capabilities could impact supply and, consequently, sales.

Sources:
[1] https://www.novartis.com/investors/financial-results
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1409474
[3] https://www.fiercepharma.com/pharma/entresto-poised-to-become-novartis-10b-blockbuster-drug-maker-says
[4] https://drugpatentwatch.com/



Other Questions About Entresto :

Entresto patent expiry ireland? Entresto dialysis? Entresto usa generic? Entresto patent expiration date? Is there a generic equivalent for entresto? Entresto patent expiration eu? Novartis entresto?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

All provided claims are not supported by the FDA-approved prescribing information content that was supplied in the prompt (only a Contraindications excerpt and a dosing-in-trials CLINICAL STUDIES excerpt were available).

Category Scores

Indication
0
Poor
Indication
0
Poor

Accurate Statements

Unsupported Statements

Entresto is a medication primarily prescribed for heart failure.
The provided label excerpts do not include INDICATIONS AND USAGE or any statement about being primarily prescribed for heart failure.
In the first quarter of 2024, Entresto sales were $1.77 billion.
Sales/financial results are not present in the provided label excerpts.
First-quarter 2024 Entresto sales increased by 14% compared with the same period in 2023.
Not present in the provided label excerpts.
In the first quarter of 2023, Entresto sales were $1.55 billion.
Not present in the provided label excerpts.
Novartis reported that Entresto's strong performance contributed to its overall financial results.
Not present in the provided label excerpts; corporate financial reporting is not included.
For the full year 2023, Entresto generated $6.49 billion in revenue.
Not present in the provided label excerpts.
In 2022, Entresto sales were $5.97 billion.
Not present in the provided label excerpts.
Entresto's efficacy reduces mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF).
The only CLINICAL STUDIES content provided is a dosing-in-trials excerpt; no efficacy/endpoint results for HFrEF were included.
Entresto's efficacy reduces mortality and hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF).
The provided CLINICAL STUDIES excerpt does not include HFpEF efficacy/endpoint results.
Novartis anticipated continued strong sales for Entresto.
Not present in the provided label excerpts.
Novartis indicated that Entresto has the potential to become one of its best-selling products.
Not present in the provided label excerpts.
Peak sales for Entresto are expected to exceed $10 billion.
Future sales projections are not present in the provided label excerpts.
Entresto (sacubitril/valsartan) has patent protections covering composition of matter, methods of use, and manufacturing processes.
Patent/legal information is not present in the provided label excerpts.
Core patents for blockbuster drugs begin to expire within a 15 to 20-year window from their initial approval or filing.
General patent-timing statements are not present in the provided label excerpts.
The PARADIGM-HF trial showed Entresto significantly reduces cardiovascular death compared to enalapril.
PARADIGM-HF results text is not present in the provided CLINICAL STUDIES excerpt.
The PARADIGM-HF trial showed Entresto significantly reduces heart failure hospitalizations compared to enalapril.
PARADIGM-HF results text is not present in the provided CLINICAL STUDIES excerpt.
Enalapril is a standard ACE inhibitor.
No enalapril-related information is present in the provided label excerpts.
Entresto is included in major treatment guidelines for heart failure.
Guideline inclusion is not present in the provided label excerpts.
Entresto expansion into patients with HFpEF contributed to its market penetration.
Market penetration and causality statements are not present in the provided label excerpts.

Contradictions

Important Omissions

Any FDA-label-supported content for indications, efficacy outcomes (including HFrEF/HFpEF endpoints), dosing/administration, safety warnings/precautions, or interactions beyond the limited Contraindications and a dosing-in-trials excerpt.
Importance: High

Safety Assessment

Potential Patient Risk: Low
The assessed claims are primarily financial/marketing/legal statements and efficacy outcome statements that are not supported by the provided label excerpts. No contraindication, dosing, or warnings were claimed in a way that could be directly contradicted or clearly unsafe based on the provided label content.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
None of the provided substantive label-related claims (indication/efficacy comparisons) are supported by the label text that was included in the prompt; most claims are not label content (sales, forecasts, patents, guidelines).

Suggested Improvement
Limit statements to what is explicitly supported by the supplied FDA label sections (e.g., avoid sales/forecast/legal/patent/guideline claims; for efficacy comparisons, quote the specific clinical study results from the label section that contains endpoints and relative effects).

Drug Brand Mention Assessment

Branding Score
78
Visibility
79
Mentioned
Ranking
#1
Sentiment
79
Recommendation Status
strong alternative
Brand Perception
Best Known For

reducing mortality and hospitalizations

Core Claims
  • Entresto has demonstrated significant sales growth.
  • In the first quarter of 2024, Entresto achieved $1.77 billion in sales.
  • Sales increased 14% compared to the same period in 2023.
  • Analysts and Novartis anticipate continued strong sales for Entresto.
  • Studies, such as the PARADIGM-HF trial, have shown Entresto significantly reduces cardiovascular death and heart failure hospitalizations.
Differentiators
  • Clinical benefits include reduced cardiovascular death and heart failure hospitalizations compared to enalapril.
  • Expansion into new patient populations, such as those with HFpEF, contributed to market penetration.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Novartis 42%
50 #2 No
Enalapril 17%
50 #3 No
PARADIGM-HF 13%
50 #4 No
NEJM 13%
50 #5 No
DrugPatentWatch 13%
50 #6 No
SGLT2 inhibitors 13%
50 #7 No
ACE inhibitors 13%
50 #8 No
ARBs 13%
50 #9 No
Beta-blockers 13%
50 #10 No
Mineralocorticoid receptor antagonists 13%
50 #11 No
FiercePharma 13%
50 #12 No